Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one ...

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI® (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by ...

Stemtech Corporation Appoints Dr. Lizette Leos, MD To Chief Scientific Officer

NAPLES, FL / ACCESS Newswire / January 6, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, is proud to appoint Dr. Lizette Leos, MD to Chief Scientific Officer. (Stem ...

The Year in Neanderthals

They drew with crayons, possibly fed on maggots and maybe even kissed us: Forty millenniums later, our ancient human cousins ...
Gut

CD48 is a novel immune checkpoint on tumour‐associated macrophages in hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Investing.com Nigeria

Actuate Therapeutics stock rises on positive pediatric cancer trial data

The clinical-stage biopharmaceutical company announced that its Phase 1 trial showed significant responses in difficult-to-treat pediatric cancers, including two Complete Metabolic Responses in ...